DOSAGE AND ADMINISTRATION
The recommended dose of AROMASIN in early and advanced breast
cancer is one 25 mg tablet once daily after a meal.
In postmenopausal women with early breast cancer who have been treated with
2–3 years of tamoxifen, treatment with AROMASIN should continue in the absence
of recurrence or contralateral breast cancer until completion of five years of
adjuvant endocrine therapy.
For patients with advanced breast cancer, treatment with AROMASIN should
continue until tumor progression is evident.
For patients receiving AROMASIN with a potent CYP 3A4 inducer such as
rifampicin or phenytoin, the recommended dose of AROMASIN is 50 mg once daily
after a meal.
The safety of chronic dosing in patients with moderate or severe hepatic or
renal impairment has not been studied. Based on experience with exemestane at
repeated doses up to 200 mg daily that demonstrated a moderate increase in
non-life threatening adverse events, dosage adjustment does not appear to be
necessary (see CLINICAL PHARMACOLOGY, Special
Populations and PRECAUTIONS).